Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo Trials

Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo	Welcome, Profile Billing Logout

43 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Catania, Gioacchino

BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

650

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

ARISE, NCT06205498: Acalabrutinib Real World Italian obSErvational Study -

Recruiting

N/A

190

Europe

acalabrutinib, Calquence

AstraZeneca, Yghea

Chronic Lymphocytic Leukemia

02/30

NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Not yet recruiting

N/A

125

Europe

Zanubrutinib

Fondazione Italiana Linfomi - ETS

Waldenström's Macroglobulinemia (WM)

07/26

ZanOs, NCT06823960: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Recruiting

N/A

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Marginal Zone Lymphoma(MZL)

06/25

FIL_FollVax22, NCT06070961: Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance

Recruiting

N/A

Europe

Cellular immunity vs SARS-CoV-2, Humoral immunity vs SARS-CoV-2, Cellular immunity vs Varicella Zoster Virus, Humoral immunity vs Varicella Zoster Virus, Diphtheria toxin-binding IgG, Tetanus toxoid-binding IgG, T-cell populations and markers characterization

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

05/27

Pietrasanta, Daniela

BRUIN CLL-321, NCT04666038: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

238

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

08/23

05/27

CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Terminated

Europe

Rituximab, Chemotherapy, Tenofovir alafenamide

Gruppo Italiano Malattie EMatologiche dell'Adulto

Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia

05/24

MOLTO, NCT04082897 / 2018-005028-40: ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting

Europe

Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet

Niguarda Hospital

CLL Transformation

09/26

12/26

GIMEMA, NCT04282811: Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy

Recruiting

N/A

321

Europe

Venetoclax

Gruppo Italiano Malattie EMatologiche dell'Adulto

Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia

01/23

10/25

GIMEMA, NCT04867915: Study on the Diagnosis and Management of CLL in Italy by

Recruiting

N/A

12500

Europe

Gruppo Italiano Malattie EMatologiche dell'Adulto

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type

10/26

Gionchetti, Paolo

VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting

672

Europe, Canada, US, RoW

Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C

Alimentiv Inc., Takeda Development Center Americas, Inc.

Colitis, Ulcerative

03/26

ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting

612

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting

268

Europe, Canada, Japan, US, RoW

TAK-279, Zasocitinib, Placebo

Takeda

Crohn's Disease

09/26

07/27

NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting

207

Europe, Canada, Japan, US, RoW

TAK-279, Zasocitinib, Placebo

Takeda

Ulcerative Colitis

09/26

08/27

ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting

212

Europe, US, RoW

Obefazimod, Placebo

Abivax S.A.

Moderately to Severely Active Crohn Disease

12/26

04/28

NCT06774638: Diagnostic and Prognostic Biomarkers in SARS-CoV-2 Infections

Completed

N/A

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

IBD - Inflammatory Bowel Disease, COVID - 19

12/21

03/24

NCT06802887: Long-term Treatment with Ustekinumab in Patients with Crohn's Disease and Ulcerative Colitis: a Cohort Study

Recruiting

N/A

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

IBD - Inflammatory Bowel Disease

12/24

12/25

Ladetto, Marco

FIL FLAZ12, NCT01827605 / 2012-000251-14: A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

Active, not recruiting

159

Europe

ZEVALIN, RIT, BEAM, ASCT

Fondazione Italiana Linfomi - ETS

Relapsed Follicular Lymphoma

10/19

01/24

TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL

Recruiting

870

Europe

R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)

Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum

Mantle Cell Lymphoma

05/21

05/26

LORELY, NCT06918912 / 2022-001147-24: Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure

Recruiting

Europe

Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)

Istituto Clinico Humanitas

Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), B-Cell Lymphoma Treatment, Relapsed or Refractory Lymphoma

03/25

06/27

FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting

Europe

Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

09/28

09/33

FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting

Europe

Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)

Fondazione Italiana Linfomi - ETS

Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma

04/26

04/29

NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting

N/A

250

Europe

Ospedale di Circolo - Fondazione Macchi

SARS-CoV-2 Infection, Hematological Malignancies

10/22

NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting

N/A

Europe

Fondazione Italiana Linfomi - ETS

Mantle Cell Lymphoma

03/25

FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting

N/A

1500

Europe

"novel" MAB (alone or in combination)

Fondazione Italiana Linfomi - ETS, Roche Pharma AG

Non-Hodgkin Lymphoma, B-cell

10/38

Maconi, Giovanni

VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Recruiting

304

Europe, Canada, US, RoW

Vedolizumab

Alimentiv Inc., Takeda

Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn

01/27

09/28

ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting

612

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

SUNRISE, NCT05192863: A Study of Vedolizumab in Adults With Crohn's Disease (CD)

Active, not recruiting

N/A

Europe, Canada, RoW

No Intervention

Takeda

Crohn's Disease

10/25

D'Amario, Domenico

RIALTO PRO, NCT06281067: Reassessment of myocardIAL Bridge TOwards PeRsOnalized Medicine

Recruiting

N/A

500

Europe

"full-physiology approach" arm, "standard approach" arm

Azienda Ospedaliero Universitaria Maggiore della Carita, Università degli Studi del Piemonte Orientale "Amedeo Avogadro"

Myocardial Bridge

01/26

ORIGAMI II, NCT06285942: EdOxaban in fRagIle Patients With Percutaneous Endoscopic GAstrostoMy and atrIal fIbrIllation

Recruiting

N/A

168

Europe

Edoxaban, No Edoxaban

Azienda Ospedaliero Universitaria Maggiore della Carita

Atrial Fibrillation, Fragility

01/25

FAST III, NCT04931771: Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR Guided Revascularization

Recruiting

N/A

2228

Europe

vFFR guided revascularization, FFR guided revascularization

ECRI bv, Siemens Healthineers AG, Pie Medical Imaging

Coronary Artery Disease

05/25

AIR-STEMI, NCT05818475: Functional Coronary Angiography Guided Revascularization in STEMI

Active, not recruiting

N/A

1823

Europe, RoW

Angiography-guided PCI, Angiography-derived FFR PCI indication and planning

University Hospital of Ferrara

Myocardial Infarction

01/26

01/28

RIALTO, NCT05111418: Myocardial Bridge Evaluation Towards Personalised Medicine: the Registry

Completed

N/A

444

Europe

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Myocardial Bridge

03/22

03/23

Farias, Danielle Leao Cordeiro de

LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

	Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
	Sep 2021 - Dec 2021 : Submission for r/r DLBCL

Active, not recruiting

440

Europe, Canada, Japan, US, RoW

Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin

ADC Therapeutics S.A., ADC Therapeutics SA

Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

06/25

06/28

BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

650

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

Bonito, Debora Rodrigues

BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting

500

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa

Loxo Oncology, Inc., Eli Lilly and Company

Lymphoma, Mantle-Cell

01/27

04/28

BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

650

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

Condino, Giovanna

ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting

612

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

Ikoma, Kyoko

ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting

612

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Catania, Gioacchino

BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

650

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

ARISE, NCT06205498: Acalabrutinib Real World Italian obSErvational Study -

Recruiting

N/A

190

Europe

acalabrutinib, Calquence

AstraZeneca, Yghea

Chronic Lymphocytic Leukemia

02/30

Not yet recruiting

N/A

125

Europe

Zanubrutinib

Fondazione Italiana Linfomi - ETS

Waldenström's Macroglobulinemia (WM)

07/26

ZanOs, NCT06823960: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Recruiting

N/A

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Marginal Zone Lymphoma(MZL)

06/25

Recruiting

N/A

Europe

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

05/27

Pietrasanta, Daniela

Active, not recruiting

238

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

08/23

05/27

Terminated

Europe

Rituximab, Chemotherapy, Tenofovir alafenamide

Gruppo Italiano Malattie EMatologiche dell'Adulto

Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia

05/24

MOLTO, NCT04082897 / 2018-005028-40: ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting

Europe

Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet

Niguarda Hospital

CLL Transformation

09/26

12/26

GIMEMA, NCT04282811: Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy

Recruiting

N/A

321

Europe

Venetoclax

Gruppo Italiano Malattie EMatologiche dell'Adulto

Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia

01/23

10/25

GIMEMA, NCT04867915: Study on the Diagnosis and Management of CLL in Italy by

Recruiting

N/A

12500

Europe

Gruppo Italiano Malattie EMatologiche dell'Adulto

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type

10/26

Gionchetti, Paolo

VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting

672

Europe, Canada, US, RoW

Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C

Alimentiv Inc., Takeda Development Center Americas, Inc.

Colitis, Ulcerative

03/26

ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting

612

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting

268

Europe, Canada, Japan, US, RoW

TAK-279, Zasocitinib, Placebo

Takeda

Crohn's Disease

09/26

07/27

NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting

207

Europe, Canada, Japan, US, RoW

TAK-279, Zasocitinib, Placebo

Takeda

Ulcerative Colitis

09/26

08/27

ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting

212

Europe, US, RoW

Obefazimod, Placebo

Abivax S.A.

Moderately to Severely Active Crohn Disease

12/26

04/28

NCT06774638: Diagnostic and Prognostic Biomarkers in SARS-CoV-2 Infections

Completed

N/A

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

IBD - Inflammatory Bowel Disease, COVID - 19

12/21

03/24

NCT06802887: Long-term Treatment with Ustekinumab in Patients with Crohn's Disease and Ulcerative Colitis: a Cohort Study

Recruiting

N/A

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

IBD - Inflammatory Bowel Disease

12/24

12/25

Ladetto, Marco

FIL FLAZ12, NCT01827605 / 2012-000251-14: A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

Active, not recruiting

159

Europe

ZEVALIN, RIT, BEAM, ASCT

Fondazione Italiana Linfomi - ETS

Relapsed Follicular Lymphoma

10/19

01/24

TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL

Recruiting

870

Europe

R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)

Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum

Mantle Cell Lymphoma

05/21

05/26

Recruiting

Europe

Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)

Istituto Clinico Humanitas

Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), B-Cell Lymphoma Treatment, Relapsed or Refractory Lymphoma

03/25

06/27

FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting

Europe

Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

09/28

09/33

FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting

Europe

Fondazione Italiana Linfomi - ETS

Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma

04/26

04/29

NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting

N/A

250

Europe

Ospedale di Circolo - Fondazione Macchi

SARS-CoV-2 Infection, Hematological Malignancies

10/22

NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting

N/A

Europe

Fondazione Italiana Linfomi - ETS

Mantle Cell Lymphoma

03/25

FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting

N/A

1500

Europe

"novel" MAB (alone or in combination)

Fondazione Italiana Linfomi - ETS, Roche Pharma AG

Non-Hodgkin Lymphoma, B-cell

10/38

Maconi, Giovanni

VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Recruiting

304

Europe, Canada, US, RoW

Vedolizumab

Alimentiv Inc., Takeda

Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn

01/27

09/28

ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting

612

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

SUNRISE, NCT05192863: A Study of Vedolizumab in Adults With Crohn's Disease (CD)

Active, not recruiting

N/A

Europe, Canada, RoW

No Intervention

Takeda

Crohn's Disease

10/25

D'Amario, Domenico

RIALTO PRO, NCT06281067: Reassessment of myocardIAL Bridge TOwards PeRsOnalized Medicine

Recruiting

N/A

500

Europe

"full-physiology approach" arm, "standard approach" arm

Azienda Ospedaliero Universitaria Maggiore della Carita, Università degli Studi del Piemonte Orientale "Amedeo Avogadro"

Myocardial Bridge

01/26

ORIGAMI II, NCT06285942: EdOxaban in fRagIle Patients With Percutaneous Endoscopic GAstrostoMy and atrIal fIbrIllation

Recruiting

N/A

168

Europe

Edoxaban, No Edoxaban

Azienda Ospedaliero Universitaria Maggiore della Carita

Atrial Fibrillation, Fragility

01/25

FAST III, NCT04931771: Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR Guided Revascularization

Recruiting

N/A

2228

Europe

vFFR guided revascularization, FFR guided revascularization

ECRI bv, Siemens Healthineers AG, Pie Medical Imaging

Coronary Artery Disease

05/25

AIR-STEMI, NCT05818475: Functional Coronary Angiography Guided Revascularization in STEMI

Active, not recruiting

N/A

1823

Europe, RoW

Angiography-guided PCI, Angiography-derived FFR PCI indication and planning

University Hospital of Ferrara

Myocardial Infarction

01/26

01/28

RIALTO, NCT05111418: Myocardial Bridge Evaluation Towards Personalised Medicine: the Registry

Completed

N/A

444

Europe

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Myocardial Bridge

03/22

03/23

Farias, Danielle Leao Cordeiro de

LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

	Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
	Sep 2021 - Dec 2021 : Submission for r/r DLBCL

Active, not recruiting

440

Europe, Canada, Japan, US, RoW

Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin

ADC Therapeutics S.A., ADC Therapeutics SA

Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

06/25

06/28

BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

650

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

Bonito, Debora Rodrigues

BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting

500

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa

Loxo Oncology, Inc., Eli Lilly and Company

Lymphoma, Mantle-Cell

01/27

04/28

BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

650

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

Condino, Giovanna

ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting

612

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

Ikoma, Kyoko

ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting

612

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites